Review began 11/03/2022 review ended 12/25/2022 published 12/28/2022 © copyright

HIGHLIGHTS

• who: Cardiovascular Events and colleagues from the (UNIVERSITY) have published the research: Review began 11/03/2022 Review ended 12/25/2022 Published 12/28/2022 u00a9 Copyright, in the Journal: (JOURNAL) of December/28,/2022
• what: The authors evaluated the impact of empagliflozin on a composite primary outcome of CV death or hospital admission for HF in individuals with T2DM and HFrEF at high risk for CVDs and events. The authors compared only empagliflozin as a combination therapy with a non-empagliflozin group of T2DM patients.
• how: In this study investigation the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.